{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:28:58Z","timestamp":1778862538847,"version":"3.51.4"},"reference-count":78,"publisher":"JLE","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.nephro.2018.02.010","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T15:31:14Z","timestamp":1522337474000},"page":"S13-S21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"S1","title":["Treatment of IgA nephropathy: Recent advances and prospects"],"prefix":"10.1684","volume":"14","author":[{"given":"Rosanna","family":"Coppo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2018.02.010_bib0395","first-page":"694","article-title":"Intercapillary deposits of IgA-IgG","volume":"74","author":"Berger","year":"1968","journal-title":"J Urol Nephrol (Paris)"},{"key":"10.1016\/j.nephro.2018.02.010_bib0400","first-page":"709","article-title":"The commonest glomerulonephritis in the world: IgA nephropathy","volume":"64","author":"D\u2019Amico","year":"1987","journal-title":"Q J Med"},{"key":"10.1016\/j.nephro.2018.02.010_bib0405","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/ndt\/gfq665","article-title":"The incidence of primary glomerulonephritis worldwide: a systematic review of the literature","volume":"26","author":"McGrogan","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2018.02.010_bib0410","article-title":"Glomerular disease frequencies by race, sex, and region: from the International Kidney Biopsy Survey (IKBS)","author":"O'Shaughnessy","year":"2017","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.nephro.2018.02.010_bib0415","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40620-016-0360-z","article-title":"Clinical and histological risk factors for progression of IgA nephropathy: an update in children, young and adult patients","volume":"30","author":"Coppo","year":"2017","journal-title":"J Nephrol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0420","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00005792-198501000-00004","article-title":"Idiopathic IgA mesangial nephropathy. Clinical and histological study of 374 patients","volume":"64","author":"D\u2019Amico","year":"1985","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nephro.2018.02.010_bib0425","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000414332","article-title":"The secretory immune system","volume":"39","author":"Vaerman","year":"1987","journal-title":"Antibiot Chemother"},{"key":"10.1016\/j.nephro.2018.02.010_bib0430","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1002\/eji.1830191210","article-title":"Anti-inflammatory activity of human IgA antibodies and their Fab alpha fragments: inhibition of IgG-mediated complement activation","volume":"19","author":"Russell","year":"1989","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0435","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1155\/S0962935196000269","article-title":"Dimeric and polymeric IgA, but not monomeric IgA, enhance the production of IL-6 by human renal mesangial cells","volume":"5","author":"Reterink","year":"1996","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.nephro.2018.02.010_bib0440","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1111\/j.1523-1755.2004.05407.x","article-title":"Aberrant glycosylation in IgA nephropathy (IgAN)","volume":"65","author":"Coppo","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2018.02.010_bib0445","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/ndt\/gfm581","article-title":"Synthesis of TNF-alpha by mesangial cells cultured with polymeric anionic IgA \u2013\u00a0role of MAPK and NF-kappa B","volume":"23","author":"Leung","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2018.02.010_bib0450","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2174\/1566524054553450","article-title":"Molecular basis of IgA nephropathy","volume":"5","author":"Lai","year":"2005","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.nephro.2018.02.010_bib0455","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.rinim.2012.08.002","article-title":"In vitro-generated immune complexes containing galactose-deficient IgA1 stimulate proliferation of mesangial cells","volume":"2","author":"Yanagihara","year":"2012","journal-title":"Results Immunol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0460","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/nri3322","article-title":"New concepts in the generation and functions of IgA","volume":"12","author":"Pabst","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0465","first-page":"935","article-title":"Steroid therapy in IgA nephropathy: a prospective pilot study in moderate proteinuric cases","volume":"61","author":"Kobayashi","year":"1986","journal-title":"Q J Med"},{"key":"10.1016\/j.nephro.2018.02.010_bib0470","first-page":"1135","article-title":"Effect of corticosteroids on renal function in progressive IgA nephropathy: long-term follow-up study","volume":"30","author":"Kobayashi","year":"1988","journal-title":"Nihon Jinzo Gakkai Shi"},{"key":"10.1016\/j.nephro.2018.02.010_bib0475","doi-asserted-by":"crossref","first-page":"244","DOI":"10.7326\/0003-4819-139-4-200308190-00006","article-title":"Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis","volume":"139","author":"Jafar","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nephro.2018.02.010_bib0480","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1111\/j.1523-1755.2004.00874.x","article-title":"Mesangial expression of angiotensin II receptor in IgA nephropathy and its regulation by polymeric IgA1","volume":"66","author":"Lai","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2018.02.010_bib0485","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/01.ASN.0000068460.37369.DC","article-title":"Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial","volume":"14","author":"Praga","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0490","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1681\/ASN.2006040347","article-title":"IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria","volume":"18","author":"Coppo","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0495","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.ajkd.2006.01.017","article-title":"Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study","volume":"47","author":"Li","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2018.02.010_bib0500","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0505","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/ki.2015.252","article-title":"New developments in the genetics, pathogenesis, and therapy of IgA nephropathy","volume":"88","author":"Magistroni","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2018.02.010_bib0510","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","article-title":"Corticosteroids in IgA nephropathy: a randomised controlled trial","volume":"353","author":"Pozzi","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2018.02.010_bib0515","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","article-title":"Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy","volume":"24","author":"Manno","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2018.02.010_bib0520","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.ajkd.2008.07.029","article-title":"Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial","volume":"53","author":"Lv","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2018.02.010_bib0525","first-page":"139","article-title":"Kidney disease: improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis. Immunoglobulin A nephropathy","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.nephro.2018.02.010_bib0530","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","article-title":"Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial","volume":"15","author":"Pozzi","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0535","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1681\/ASN.V131142","article-title":"Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy","volume":"13","author":"Ballardie","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0540","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/ndt\/gfg081","article-title":"Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide","volume":"18","author":"Tumlin","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2018.02.010_bib0545","first-page":"103","article-title":"The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial","volume":"34","author":"Walker","year":"1990","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0550","first-page":"60","article-title":"Effects of triple therapy in IgA nephritis: a follow-up study 5 years later","volume":"36","author":"Woo","year":"1991","journal-title":"Clin Nephrol"},{"issue":"8","key":"10.1016\/j.nephro.2018.02.010_bib0555","first-page":"CD003965","article-title":"Immunosuppressive agents for treating IgA nephropathy","author":"Vecchio","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.nephro.2018.02.010_bib0560","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/ki.2014.63","article-title":"Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments","volume":"86","author":"Coppo","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2018.02.010_bib0565","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/ki.2009.243","article-title":"The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification","volume":"76","author":"Cattran","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2018.02.010_bib0570","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/ki.2010.43","article-title":"The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults","volume":"77","author":"Coppo","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2018.02.010_bib0575","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1053\/j.ajkd.2013.04.021","article-title":"Evaluation of the Oxford classification of IgA nephropathy: a systematic review and meta-analysis","volume":"62","author":"Lv","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2018.02.010_bib0580","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00467-016-3469-3","article-title":"Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort","volume":"32","author":"Coppo","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0585","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1681\/ASN.2014070697","article-title":"Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study","volume":"26","author":"Tesar","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0590","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2018.02.010_bib0595","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1681\/ASN.2016060647","article-title":"Corticosteroids in IgA nephropathy: lessons from recent studies","volume":"28","author":"Coppo","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0600","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.ajkd.2016.02.042","article-title":"Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis","volume":"68","author":"Inker","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.nephro.2018.02.010_bib0605","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1681\/ASN.2017060713","article-title":"Effects of two immunosuppressive treatment protocols for IgA nephropathy","volume":"29","author":"Rauen","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0610","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/nrneph.2013.59","article-title":"Treatment of IgA nephropathy and Henoch-Sch\u00f6nlein nephritis","volume":"9","author":"Floege","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0615","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.nephro.2018.02.010_bib0620","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1681\/ASN.2011111112","article-title":"Corticosteroid therapy in IgA nephropathy","volume":"23","author":"Lv","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0625","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2215\/CJN.02300215","article-title":"Changes in proteinuria and side effects of corticosteroids alone or in combination with azathioprine at different stages of IgA nephropathy","volume":"11","author":"Sarcina","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.nephro.2018.02.010_bib0630","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12882-017-0647-x","article-title":"Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis","volume":"18","author":"Du","year":"2017","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0635","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1053\/j.ajkd.2016.11.027","article-title":"Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial","volume":"69","author":"Hou","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"suppl. 1","key":"10.1016\/j.nephro.2018.02.010_bib0640","doi-asserted-by":"crossref","first-page":"i123","DOI":"10.1093\/ndt\/gfw326","article-title":"Mycophenolate mofetil therapy in immunoglobulin A nephropathy: histological changes after treatment","volume":"32","author":"Beckwith","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2018.02.010_bib0645","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0650","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12882-017-0467-z","article-title":"Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis","volume":"18","author":"Song","year":"2017","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0655","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40620-015-0227-8","article-title":"Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression","volume":"29","author":"Chakera","year":"2016","journal-title":"J Nephrol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0660","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40620-014-0165-x","article-title":"Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation","volume":"28","author":"Shen","year":"2015","journal-title":"J Nephrol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0665","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1681\/ASN.V101101","article-title":"A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese pediatric IgA nephropathy treatment study group","volume":"10","author":"Yoshikawa","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0670","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2215\/CJN.08630910","article-title":"Long-term results of a randomized controlled trial in childhood IgA nephropathy","volume":"6","author":"Kamei","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0675","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/ki.2015.322","article-title":"The MEST score provides earlier risk prediction in IgA nephropathy","volume":"89","author":"Barbour","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2018.02.010_bib0680","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.kint.2016.09.029","article-title":"Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy","volume":"91","author":"Bellur","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2018.02.010_bib0685","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford Classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2018.02.010_bib0690","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1681\/ASN.2016040433","article-title":"A multicenter study of the predictive value of crescents in IgA nephropathy","volume":"28","author":"Haas","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0695","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00467-016-3390-9","article-title":"Biomarkers and targeted new therapies for IgA nephropathy","volume":"32","author":"Coppo","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0700","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00467-017-3652-1","article-title":"The gut\u2013kidney axis in IgA nephropathy: role of microbiota and diet on genetic predisposition","volume":"33","author":"Coppo","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0705","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/ng.787","article-title":"Genome-wide association study identifies susceptibility loci for IgA nephropathy","volume":"43","author":"Gharavi","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.nephro.2018.02.010_bib0710","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1172\/JCI45563","article-title":"Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy","volume":"121","author":"McCarthy","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nephro.2018.02.010_bib0715","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3892\/mmr.2017.6190","article-title":"Expression profile of BAFF in peripheral blood from patients of IgA nephropathy: correlation with clinical features and Streptococcus pyogenes infection","volume":"15","author":"Zheng","year":"2017","journal-title":"Mol Med Rep"},{"issue":"6","key":"10.1016\/j.nephro.2018.02.010_bib0720","doi-asserted-by":"crossref","first-page":"e99006","DOI":"10.1371\/journal.pone.0099006","article-title":"Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN)","volume":"9","author":"De Angelis","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.nephro.2018.02.010_bib0725","first-page":"499","article-title":"Gluten-induced experimental IgA glomerulopathy","volume":"60","author":"Coppo","year":"1989","journal-title":"Lab Invest"},{"key":"10.1016\/j.nephro.2018.02.010_bib0730","first-page":"72","article-title":"Effects of a gluten-free diet in primary IgA nephropathy","volume":"33","author":"Coppo","year":"1990","journal-title":"Clin Nephrol"},{"issue":"suppl. 10","key":"10.1016\/j.nephro.2018.02.010_bib0735","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1681\/ASN.V210s173","article-title":"Dietary antigens and primary immunoglobulin A nephropathy","volume":"2","author":"Coppo","year":"1992","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0740","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/ki.2015.94","article-title":"Gluten exacerbates IgA nephropathy in humanized mice through gliadin\u2013CD89 interaction","volume":"88","author":"Papista","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2018.02.010_bib0745","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1093\/ndt\/gfr052","article-title":"New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria","volume":"26","author":"Smerud","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2018.02.010_bib0750","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial","volume":"389","author":"Fellstr\u00f6m","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2018.02.010_bib0755","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1681\/ASN.2014101000","article-title":"Current understanding of the role of complement in IgA nephropathy","volume":"26","author":"Maillard","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0760","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00467-016-3575-2","article-title":"C4d deposits in IgA nephropathy: where does complement activation come from?","volume":"32","author":"Coppo","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0765","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2215\/CJN.09710913","article-title":"Association of C4d deposition with clinical outcomes in IgA nephropathy","volume":"9","author":"Espinosa","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2018.02.010_bib0770","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/ki.2008.579","article-title":"Upregulation of the immunoproteasome in peripheral blood mononuclear cells of patients with IgA nephropathy","volume":"75","author":"Coppo","year":"2009","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.nephro.2018.02.010_bib0775","doi-asserted-by":"crossref","first-page":"e1002765","DOI":"10.1371\/journal.pgen.1002765","article-title":"Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis","volume":"8","author":"Kiryluk","year":"2012","journal-title":"PLoS Genet"},{"key":"10.1016\/j.nephro.2018.02.010_bib0780","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1681\/ASN.2015080856","article-title":"IgA1 protease treatment reverses mesangial deposits and hematuria in a model of IgA nephropathy","volume":"27","author":"Lechner","year":"2016","journal-title":"J Am Soc Nephrol"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725518300257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725518300257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2018.02.010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:12:48Z","timestamp":1741191168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725518300257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":78,"alternative-id":["S1769725518300257"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2018.02.010","relation":{},"ISSN":["1769-7255"],"issn-type":[{"value":"1769-7255","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of IgA nephropathy: Recent advances and prospects","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2018.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 francophone de n\u00e9phrologie, dialyse et transplantation. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}